+ Filter
Loading...
E2
Loading...Anti-E2 Products
- Recombinant Human Anti-VEEV E2 Antibody (F5) (PABL-357)
-
- Derivation: Human
- Species Reactivity: VEEV
- Type: IgG
- Application: WB, ELISA, Neut, FuncS
Compare
- Recombinant Rat Anti-HCV E2 Antibody (3/11) (PABL-118)
-
- Derivation: Rat
- Species Reactivity: HCV
- Type: IgG
- Application: WB, ELISA, Neut, FuncS
Compare
- Human Anti-E2 Recombinant Antibody (clone D12) (HPAB-2105-FY)
-
- Species Reactivity: Human
- Type: Human IgG
- Application: ELISA
Compare
- Mouse Anti-E2 Antibody (clone mAb#8), mRNA (PABZ-180-mRNA)
-
- Species Reactivity: HCV
Compare
- Mouse Anti-E2 Antibody (clone mAb 12), mRNA (PABL-465-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone F5), mRNA (PABL-357-mRNA)
-
- Species Reactivity: VEEV
Compare
- Human Anti-E2 Antibody (PABL-124-mRNA), mRNA (PABL-124-mRNA)
-
- Species Reactivity: HCV
Compare
- Mouse Anti-E2 Antibody (clone mAb8), mRNA (PABL-123-mRNA)
-
- Species Reactivity: HCV
Compare
- Mouse Anti-E2 Antibody (clone mAb12), mRNA (PABL-122-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone TRN-1007), mRNA (HPAB-N0075-YC-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone TRN-1008), mRNA (HPAB-N0074-YC-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone HC84.26.5D), mRNA (HPAB-N0072-YC-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone hu5B3.v3), mRNA (PABZ-181-mRNA)
-
- Species Reactivity: HCV
Compare
- Mouse Anti-E2 Antibody (clone HC84-27), mRNA (PABL-121-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone HC84-1), mRNA (PABL-120-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone HC33.1), mRNA (PABL-119-mRNA)
-
- Species Reactivity: HCV
Compare
- Human Anti-E2 Antibody (clone mAb1:7), mRNA (PABC-184-mRNA)
-
- Species Reactivity: HCV
Compare
-
- Class: Class II
- Antigen: E2
- Antigen Species: HPV
- Peptide: MEAIAKRLDACQDQLLELYE
- Conjugate: BV421
Compare
-
- Class: Class II
- Antigen: E2
- Antigen Species: HPV
- Peptide: MEAIAKRLDACQDQLLELYE
- Conjugate: FITC
Compare
- DRB1*03:01/HPV E2 (PIVQLQGDSNCLKCFR) MHC Monomer (MHC-YF094)
-
- Class: Class II
- Antigen: E2
- Antigen Species: HPV
- Peptide: PIVQLQGDSNCLKCFR
- Conjugate: Biotin
Compare
-
- Class: Class II
- Antigen: E2
- Antigen Species: HPV
- Peptide: MEAIAKRLDACQDQLLELYE
- Conjugate: PE
Compare
-
- Class: Class II
- Antigen: E2
- Antigen Species: HPV
- Peptide: MEAIAKRLDACQDQLLELYE
- Conjugate: APC
Compare
-
- Class: Class II
- Antigen: E2
- Antigen Species: HPV
- Peptide: MEAIAKRLDACQDQLLELYE
- Conjugate: Biotin
Compare
- Anti-HCV E2 Recombinant Antibody Fab Fragment (Y47W) (TAB-239CT-F(E))
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody Fab Fragment (Y47F) (TAB-238CT-F(E))
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody scFv Fragment (Y47W) (TAB-239CT-S(P))
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody scFv Fragment (Y47F) (TAB-238CT-S(P))
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody (Y47W) (TAB-239CT)
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Anti-HCV E2 Recombinant Antibody (Y47F) (TAB-238CT)
-
- Derivation: Phage display library
- Species Reactivity: HCV
- Type: Human antibody
- Application: ELISA, WB
Compare
- Human Anti-HCV E2 Recombinant Antibody (AP33) (TAB-020CT)
-
- Derivation: Phage display library
- Species Reactivity: genotypes 1-6 of HCV
- Type: Human antibody
- Application: ELISA, IP, Neut, FC, WB
Compare
- Recombinant Human Anti-E2 Antibody (TRN-1007) (HPAB-N0075-YC)
-
- Species Reactivity: HCV
- Type: Human IgG
- Application: Neut, ELISA, WB
Compare
- Recombinant Humanized Anti-E2 Antibody (TRN-1008) (HPAB-N0074-YC)
-
- Derivation: Humanized
- Species Reactivity: HCV
- Type: Humanized IgG
- Application: Neut, ELISA, WB
Compare
- Recombinant Human Anti-E2 Antibody (HC84.26.5D) (HPAB-N0072-YC)
-
- Species Reactivity: HCV
- Type: Human IgG
- Application: Neut, ELISA, FuncS
Compare
- Recombinant Human Anti-E2 Antibody scFv Fragment (HC84.26.5D) (HPAB-N0072-YC-S(P))
-
- Species Reactivity: HCV
- Type: Human scFv
- Application: Neut, ELISA, FuncS
Compare
- Human Anti-E2 Recombinant Antibody (clone D12); scFv Fragment (HPAB-2105-FY-S(P))
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA
Compare
- Recombinant Human Anti-E2 Antibody scFv Fragment (TRN-1007) (HPAB-N0075-YC-S(P))
-
- Species Reactivity: HCV
- Type: Human scFv
- Application: Neut, ELISA, WB
Compare
- Recombinant Humanized Anti-E2 Antibody scFv Fragment (TRN-1008) (HPAB-N0074-YC-S(P))
-
- Derivation: Humanized
- Species Reactivity: HCV
- Type: Humanized scFv
- Application: Neut, ELISA, WB
Compare
- Recombinant Human Anti-E2 Antibody Fab Fragment (TRN-1007) (HPAB-N0075-YC-F(E))
-
- Species Reactivity: HCV
- Type: Human Fab
- Application: Neut, ELISA, WB
Compare
- Recombinant Humanized Anti-E2 Antibody Fab Fragment (TRN-1008) (HPAB-N0074-YC-F(E))
-
- Derivation: Humanized
- Species Reactivity: HCV
- Type: Humanized Fab
- Application: Neut, ELISA, WB
Compare
- Recombinant Human Anti-E2 Antibody Fab Fragment (HC84.26.5D) (HPAB-N0072-YC-F(E))
-
- Species Reactivity: HCV
- Type: Human Fab
- Application: Neut, ELISA, FuncS
Compare
- Human Anti-E2 Recombinant Antibody (clone D12); Fab Fragment (HPAB-2105-FY-F(E))
-
- Species Reactivity: Human
- Type: Human Fab
- Application: ELISA
Compare
View More Products
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Background
Advances in treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) have led to high cure rates of treated patients. Although rates of sustained virologic response of approximately 95% have been achieved, a large number of patients still fail treatment, even with drug combination regiments. A high percentage of these treatment failures are due to the emergence of resistance-associated variants (RAV). Chronic HCV infection consequently will continue as a leading cause of cirrhosis and hepatocellular carcinoma, which are major indications for liver transplantation.
